This advanced study uses Amyvid™, the only radioactive diagnostic agent to be FDA-approved for PET imaging of the brain plaque associated with Alzheimer's.
(PRWeb November 02, 2012)
Read the full story at http://www.prweb.com/releases/2012/11/prweb10081369.htm
This advanced study uses Amyvid™, the only radioactive diagnostic agent to be FDA-approved for PET imaging of the brain plaque associated with Alzheimer's.
(PRWeb November 02, 2012)
Read the full story at http://www.prweb.com/releases/2012/11/prweb10081369.htm
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
